Clinical-stage company developing transformational treatments for patients with serious metabolic disease—Akero Therapeutics (NASDAQ:AKRO) priced of an upsized underwritten public offering of 5.33M shares at $48.00 per share and warrants to buy ~1.96M shares.
Underwriters have a 30-day option to purchase